Guardant Health
Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing. Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics. With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
DitchCarbon Score
How does Guardant Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guardant Health's score of 32 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guardant Health's reported carbon emissions
Guardant Health, headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established clear targets for its Scope 1 and Scope 2 emissions. Guardant Health aims to reduce these emissions to near zero by the middle of this decade, specifically targeting the years 2023 to 2025. The company's commitment to sustainability is reflected in its near-term reduction initiatives, which focus on both direct emissions (Scope 1) and indirect emissions from energy consumption (Scope 2). While no absolute emissions figures are provided, the commitment to achieving near-zero emissions demonstrates Guardant Health's proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. As of now, Guardant Health has not committed to a net-zero target but remains dedicated to its reduction goals, showcasing its responsibility towards environmental stewardship.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 1,659,000 |
| Scope 2 | 2,563,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guardant Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
